A Novel Human Amniotic Membrane Suspension Improves the Therapeutic Effect of Mesenchymal Stem Cells on Myocardial Infarction in Rats

IF 4 Q2 ENGINEERING, BIOMEDICAL

Advanced Nanobiomed Research Pub Date : 2024-09-30 DOI:10.1002/anbr.202400084

Zhaoyi Li, Meirong Zhang, Yi Wang, Yijia Li, Yi Zhun Zhu

引用次数: 0

Abstract

Mesenchymal stem cell (MSC) therapy aids cardiac repair and regeneration, but the low rate of MSC survival and engulfment in the infarcted heart remains a major obstacle for routine clinical application. Here, an injectable suspension of human acellular amniotic membrane (HAAM) that may serve as synergistic cell delivery vehicle for the treatment of myocardial infarction (MI) by improving MSC homing and survival is developed. The results demonstrate that compared with MSC transplantation alone, HAAM-loaded MSCs have higher survival and engraftment rates in infarcted tissue, alleviated hypoxia-induced myocardial damage, achieved higher improvements in cardiac function, promoted angiogenesis, and reduced myocardial fibrosis. In addition, HAAM-loaded MSCs increase N-cadherin levels and thereby enhance the efficacy of MSCs in treating MI. This study provides a new approach for MSC-based cardiac repair and regeneration.

Abstract Image

查看原文本刊更多论文

新型人羊膜悬浮液改善了间充质干细胞对大鼠心肌梗死的治疗效果

间充质干细胞疗法有助于心脏修复和再生，但间充质干细胞在梗死心脏中的存活率和吞噬率低仍是常规临床应用的主要障碍。在这里，研究人员开发了一种可注射的人无细胞羊膜（HAAM）悬浮液，这种悬浮液可通过改善间充质干细胞的归巢和存活率，作为治疗心肌梗死（MI）的协同细胞输送载体。结果表明，与单独移植间充质干细胞相比，HAAM负载的间充质干细胞在梗死组织中的存活率和移植率更高，可减轻缺氧引起的心肌损伤，改善心功能，促进血管生成，减少心肌纤维化。此外，HAAM 负载的间充质干细胞还能提高 N-cadherin 水平，从而增强间充质干细胞治疗心肌梗死的疗效。这项研究为基于间充质干细胞的心脏修复和再生提供了一种新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advanced Nanobiomed Research nanomedicine, bioengineering and biomaterials-

CiteScore

5.00

自引率

5.90%

发文量

审稿时长

21 weeks

期刊介绍： Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science. The scope of Advanced NanoBiomed Research will cover the following key subject areas: ▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging. ▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications. ▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture. ▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs. ▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization. ▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems. with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.